

1 **Effect of deleting four *Toxoplasma gondii* calcium binding EGF**
2 **domain-containing proteins on parasite replication and virulence**

3
4 **Xin-Cheng Wang¹ · Ting-Ting Li^{1,2} · Hany M. Elsheikha³ · Xiao-Nan Zheng⁴ · Dan-Yu**
5 **Zhao¹ · Jin-Lei Wang^{1,2} · Meng Wang^{1,2} · Xing-Quan Zhu^{1,4,5}**

6
7 (✉) Xing-Quan Zhu

8 xingquanzhu1@hotmail.com

9 (✉) Meng Wang

10 wangmeng02@caas.cn

11
12 ¹ State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary
13 Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of
14 Agricultural Sciences, Lanzhou, Gansu Province 730046, PR China

15 ² Institute of Urban Agriculture, Chinese Academy of Agricultural Sciences, Chengdu, Sichuan
16 Province 610213, PR China

17 ³ Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science,
18 University of Nottingham, Loughborough, LE12 5RD, UK

19 ⁴ Laboratory of Parasitic Diseases, College of Veterinary Medicine, Shanxi Agricultural
20 University, Taigu, Shanxi Province 030801, PR China

21 ⁵ Key Laboratory of Veterinary Public Health of Higher Education of Yunnan Province, College
22 of Veterinary Medicine, Yunnan Agricultural University, Kunming, PR China

23
24
25
26 **Contact information for the corresponding author:**

27 **Prof Xing-Quan Zhu**

28 **Email: xingquanzhu1@hotmail.com**

29 **Tel: +86-18793138037**

31 **Abstract**

32 Several calcium-binding proteins including calcium-dependent protein kinases, play important
33 roles in several facets of the intracellular infection cycle of the apicomplexan protozoan parasite
34 *Toxoplasma gondii*. However, the role of the calcium binding epidermal growth factor (EGF)
35 domain-containing proteins (CBDPs) remains poorly understood. In this study, we examined
36 the functions of four *CBDP* genes in *T. gondii* RH strain of Type I by generating knock-out
37 strains using CRISPR-Cas9 system. We investigated the ability of mutant strains deficient in
38 *CBDP1*, *CBDP2*, *CBDP3* or *CBDP4* to form plaques, replicate intracellularly, and egress the
39 host cells. The results showed that no definite differences between any of these four *CBDP*
40 mutant strains and the wild-type strain in terms of their ability to form plaques, intracellular
41 replication, and egress. Additionally, *CBDP* mutants did not exhibit any significant attenuated
42 virulence compared to the wild-type strain in mice. The expression profiles of *CBDP2-4* genes
43 were conserved among *T. gondii* strains of different genotypes, life cycle stages, and
44 developmental forms. Whether other *CBDP* genes play any roles in the pathogenicity of *T.*
45 *gondii* strains of different genotypes remains to be elucidated.

46

47 **Keywords:** *Toxoplasma gondii* · Calcium binding EGF domain-containing protein (CBDP) ·

48 CRISPR-Cas9 system · Gene functions

49

50

51 **Introduction**

52

53 The globally prevalent protozoan *Toxoplasma gondii* can infect humans and a large number of
54 avian and mammalian species (Elsheikha et al. 2021; Robert-Gangneux and Dardé 2012; Smith
55 et al. 2021). *T. gondii* infection occurs via ingestion of raw or poorly cooked meat containing
56 the parasite tissue cysts or drinking water contaminated with oocysts excreted in the feline feces
57 (Wang et al. 2019). *T. gondii* infection in immunocompetent individuals rarely causes any
58 clinical symptoms. However, this parasite can lead to life-threatening conditions in patients
59 with a compromised immune system, such as those with AIDS or malignancies (Elsheikha et
60 al. 2021; Wang et al. 2017). *T. gondii* can also be transmitted vertically via the placenta to the
61 fetus, which can lead to miscarriage, premature birth, fetal malformation, or stillbirth
62 (Elsheikha, 2008; Robert-Gangneux and Dardé 2012; Rico-Torres et al. 2016; Smith et al.
63 2021).

64 Ca^{2+} is a signalling molecule involved in a wide range of cellular processes in eukaryotic
65 mammalian cells and regulates the host cell invasion, parasite motility, and egress in *T. gondii*
66 (Borges-Pereira et al. 2015; Lovett and Sibley 2003; Lourido et al. 2013; Nagamune et al.
67 2008). Calcium storage organelles in *T. gondii* are located in the Golgi, endoplasmic reticulum
68 (ER), mitochondria, apicoplast, and a plant-like vacuole (Moreno and Docampo 2003; Moreno
69 et al. 2011; Pingret et al. 1996). Calcium-binding proteins (CBP) include calmodulin (CAM),
70 calmodulin neuropilin B-like proteins (CBL), and calcium-dependent protein kinases (CDPK),
71 all have highly conserved EF-chiral structural domains (Moreno et al. 2011). At least twelve
72 CDPKs (CDPK1, CDPK2, CDPK2A, CDPK2B, CDPK3, CDPK4, CDPK4A, CDPK5,
73 CDPK6, CDPK7, CDPK8 and CDPK9) are expressed in *T. gondii* (Billker et al. 2009), and
74 several CDPKs are involved in the parasites propagation. For example, *CDPK1* plays a role in
75 the motility, host-cell invasion and egress of *T. gondii* (Lourido et al. 2010), while deletion of

76 *CDPK2* causes the accumulation of starch granules in the bradyzoite stage, leading to
77 morphological defects and inhibition of cyst formation (Uboldi et al. 2015; Wang et al. 2018).
78 *CDPK3* plays important roles in parasite egress and cyst formation in the brain of mice
79 (Garrison et al. 2012; Kannan et al. 2021; Wu et al. 2022). Downregulation of *CDPK7* causes
80 division and growth defects in *T. gondii* (Morlon-Guyot et al. 2014). On the other hand,
81 *CDPK4*, *CDPK4A*, *CDPK5*, *CDPK6*, *CDPK8* and *CDPK9* are non-essential genes and are not
82 involved in the invasion, egress and intracellular proliferation or virulence of *T. gondii* (Long
83 et al. 2016; Wang et al. 2015). In calmodulin (CaM)-like proteins, calcium binds and regulates
84 the functions of many different partner proteins, including motor proteins, ion channels, and
85 other enzymes (Kursula et al. 2014). A large number of CaM proteins have been identified in
86 *T. gondii* including a single highly conserved CaM gene, and numerous CaM-like genes
87 (Nagamune and Sibley 2006). CaM1 and CaM2 are individually dispensable, but the loss of
88 both genes results in a lethal phenotype, whereas CaM3 is refractory to deletion. All three genes
89 (CaM1, CaM2 and CaM3) contribute to parasite motility, host cell invasion, and egress (Long
90 et al. 2017).

91 Epidermal growth factor (EGF) is a short peptide with a distinctive motif of six cysteines
92 which is found in many proteins and performs various functions (Davis et al. 1990). EGF or
93 EGF-like domains have been reported in many membrane-bound proteins (Appella et al. 1988;
94 Blomquist et al. 1984; Barker et al. 1986; Doolittle et al. 1984; Davis et al. 1990). In *T. gondii*,
95 TgMIC3 is a microneme protein containing five overlapping EGF-like domains (Garcia-Reguet
96 et al. 2000), which assists parasite attachment and invasion (Zhang et al. 2019). A calcium-
97 binding site has been found at the N terminus of some EGF-like domains (Selander-
98 Sunnerhagen et al. 1992). Apicomplexan parasites, such as *T. gondii*, rely on calcium as a
99 signalling molecule to regulate various cellular processes (Lourido et al. 2013). Calcium-
100 binding may be crucial for protein-protein interactions and potentially parasite protein-host

101 interactions. However, knowledge of the role of the calcium binding EGF domain-containing
102 proteins (CBDPs) in the replication and infectivity of *T. gondii* is limited.

103 Identification of the genes required for the infectivity of *T. gondii* is essential for
104 understanding the parasite intracellular replication cycle as well as development of effective
105 anti-*T. gondii* strategies. Although numerous parasite genes important for *T. gondii*
106 pathogenicity have been identified, it is likely that additional genes remain to be discovered. In
107 the present study, we sought to uncover the role *T. gondii* CBDPs in the replication and
108 virulence of *T. gondii* Type I RH strain. We investigated whether the deletion of *CBDP1*,
109 *CBDP2*, *CBDP3* and *CBDP4* using the CRISPR-Cas9 gene editing technology affects the
110 parasite plaque formation, intracellular replication, and egress. The impact of *CBDP* gene
111 deletion on the parasite virulence and acute *T. gondii* infection in mice was also investigated.

112

113 **Materials and methods**

114 **Mice and parasites**

115 Female Kunming mice of 7–8 weeks old were purchased from the Centre of Laboratory
116 Animals, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.
117 All mice were raised under specific pathogen-free and biocontainment conditions with free
118 access to water and food as well as environmental enrichment. The tachyzoites of *T. gondii* RH
119 strain (Type I) and the corresponding knockout strains were cultured in human foreskin
120 fibroblasts (HFFs, American Type Culture Collection, Manassas, VA, USA) maintained at 37
121 °C in a 5% CO₂ air atmosphere, as previously described ([Wang et al. 2020b](#)).

122

123 **Generation of *CBDP* knockout strains by CRISPR-Cas9 system**

124 The CRISPR/Cas9 target selection website (<http://www.e-crisp.org/E-CRISP/>) was used for
125 prediction of the four target genes (*TGGT1_315520*, *TGGT1_318540*, *TGGT1_269930* and

126 *TGGT1_315550*) of *T. gondii* RH strain. The details of the primers used are listed in [Table 1](#).
127 The pSAG1::CAS9-U6::sgUPRT was used as a template and the UPRT targeting guide RNA
128 was replaced with the corresponding guide RNAs using the Q5 fixed-point mutagenesis kit
129 (NEB). The primers listed in [Table 2](#) were used to amplify the 3' and 5' homologous arms of
130 each *CBDP* gene from the genomic DNA of *T. gondii* RH strain. The plasmid pUPRT-DHFR-
131 D was used as a template to amplify the DHFR fragment. The 5' and 3' homologous sequences
132 of each gene were obtained by amplification of the genomic DNA of the RH strain, and the
133 DHFR fragment was amplified from the pUPRT-DHFR-D plasmid. The above sequences were
134 inserted into the PUC19 vector using a multi-fragment cloning method using the Clone Express
135 II one-step Cloning Kit (Vazyme). After transformation, positive plasmids were identified by
136 sequencing and the positive plasmid was extracted using Endo-Free Plasmid DNA Mini Kit
137 Protocols (OMEGA). Finally, the corresponding gene specific CRISPR plasmid (30 µg) and
138 the homology construct (25 µg) were co-transfected into freshly egressed tachyzoites (n=10⁷),
139 and the positive strains were screened by 3 µM pyrimethamine. Finally, 96-well plates were
140 used to isolate single clones and *T. gondii* DNA was extracted and verified by PCR using
141 previously designed primers ([Table 3](#)) ([Wang et al. 2020a](#)).

142

143 **Assessment of the plaque formation**

144 We examined the ability of the mutant and wild-type strains to produce plaques in HFF tissue
145 culture. Briefly, HFF monolayers in 12-well culture plates were infected with 500 freshly
146 egressed tachyzoites per well. After 7 days of incubation at 37°C, the infected cell cultures were
147 washed gently with phosphate buffered saline (PBS) three times. After fixation with 4%
148 paraformaldehyde (PFA) for 10 min, the infected monolayers were stained for 15 min with 0.2%
149 crystal violet to visualize the plaques. The stained monolayers were imaged using a scanner to

150 analyse the relative size and number of plaques formed by the growing tachyzoites, as
151 previously described ([Wang et al. 2020a](#)).

152

153 **Intracellular replication of tachyzoites**

154 We investigated the effect of *CBDP* gene deletion on the intracellular replication of *T. gondii*.
155 In brief, HFF monolayers grown on 12-well culture plates were infected with 10^5 freshly
156 egressed tachyzoites per well for 1 h, and then washed with PBS to remove unbound
157 tachyzoites. The plates were incubated for further 23 h and then the cell monolayers were fixed
158 with 4% PFA and tachyzoites were stained with anti-SAG1. At least 200 parasitophorous
159 vacuoles (PVs) were examined using the microscope to determine the number of tachyzoites
160 (1, 2, 4, 8, and 16 tachyzoites) within each PV. The percentage of the PVs containing different
161 numbers of tachyzoite was calculated as previously described ([Garrison et al. 2012](#); [Shen and](#)
162 [Sibley 2014](#)).

163

164 **Egress assay**

165 HFF monolayers growing in 12-well tissue culture plates were infected with 2×10^4 tachyzoites
166 of each of the deletion strains and the wild-type RH strain. After 30-36 h of incubation, the
167 infected cells were treated with 3 μ M calcium ionophore A23187 1:1000 in Dulbecco's
168 Modified Eagle Medium and tachyzoites egress from host cells was recorded immediately by
169 time-lapse microscopic imaging as previously described ([McCoy et al. 2012](#); [Morlon-Guyot et](#)
170 [al. 2014](#)).

171

172 **Mouse infection with the mutant strains**

173 Kunming mice were infected with 100 freshly egressed tachyzoites of each of the four *CBDP*
174 knockouts or the wild-type strains (6 mice/strain) by intraperitoneal (i.p.) injection. All mice

175 were monitored and weighed daily for any clinical signs, and twice daily if they started to show
176 a change in their appetite, body weight, behavior, level of activity, or posture. Mice were
177 euthanized immediately on reaching the humane endpoint.

178

179 **Bioinformatic analysis of *T. gondii* calcium binding EGF domain-containing proteins**

180 The CBDP proteins were analyzed for the presence of functional domains using the SMART
181 tool as previously described (Zhang et al. 2020). Information on the genomic characteristics
182 (such as signal peptide, the number of exons and transmembrane domains) and time-series
183 expression data of the *CBDP* genes were obtained from the ToxoDB (Gajria et al. 2007). Data
184 was representative to *T. gondii* cell cycle phases, life cycle stages (oocyst, tachyzoite and
185 bradyzoite), and genotypes (I, II and III). We compared the cell cycle stages of the RH strain
186 for *CBDP2* (*TGGT1_318540*), *CBDP3* (*TGGT1_269930*) and *CBDP4* (*TGGT1_315550*) as
187 previously described (Behnke et al. 2010).

188

189 **Statistical analysis**

190 All statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, La Jolla,
191 CA, USA) and the level of significance was determined by one-way ANOVA or two-way
192 ANOVA as indicated in the figure legends. Survival differences were tested for statistical
193 significance by the log rank (Mantel-Cox) test. Each experiment was repeated three times, and
194 the results were shown as means \pm standard deviations (SD), and the difference was considered
195 significant when the *p*-value was < 0.05 .

196

197 **Results**

198 **Identification of the functional domains of CBDPs**

199 The prediction of the functional domains of the amino acid sequences of *TGGT1_315520*,
200 *TGGT1_318540*, *TGGT1_269930* and *TGGT1_315550* of *T. gondii* RH strain was performed
201 by using the SMART tool. We detected the presence of EGF, epidermal growth factor calcium-
202 binding (EGF-CA) and EGF-like domains, showing that these proteins are CBDPs (Fig. S1).

203

204 **Successful construction and validation of the *CBDP* knockout strains**

205 To investigate the functions of the four TgCBDPs, the CRISPR-Cas9 technique was used to
206 delete the *CBDP* genes, individually, in Type I RH strain, and the *CBDP* coding region was
207 successfully replaced by 5' UTR-DHFR-3' UTR fragment using a homologous recombination
208 system (Fig. 1A). Single clones were obtained by drug selection and limiting dilution assay.
209 The primers in Table 3 were used to validate the construction of mutant strains. As shown in
210 Fig. 1B, in the four mutant strains (*RHΔCBDP1*, *RHΔCBDP2*, *RHΔCBDP3* and *RHΔCBDP4*),
211 the PCR2 targeting ~600 bp *CBDP* fragment did not produce any amplicons, confirming the
212 absence of the targeted gene in the knocked-out strain. Additionally, replacement of DHFR
213 fragment was confirmed by PCR1 and PCR3, with ~1500 bp fragment being amplified in the
214 KO strains but was not detected in the wild-type RH strain (Fig. 1B), indicating the successful
215 construction of four *CBDP* deletion mutant strains.

216

217 **Deletion of *CBDP1-4* does not affect the parasite ability to form plaques**

218 To explore the potential involvement of *CBDP1-4* in the parasite infectivity, we began by
219 testing the effect of deleting *CBDP1-4* on the ability of *T. gondii* to form plaques in cultured
220 cells. There was no significant difference in the number or the size of the plaques between any
221 of the four knockout strains and the corresponding wild-type RH strain ($p > 0.05$, Fig. 2A-B).
222 This result suggests that *CBDP1-4* play no roles in *T. gondii* replication.

223

224 ***CBDP1-4* are not involved in the egress and replication of *T. gondii***

225 As the plaque assay is limited by the parasite's ability to cause cell lysis and plaque formation
226 in the host cell monolayer, it does not discern the changes that occur at the different stages of
227 the lytic infection cycle. Therefore, it was important to investigate additional properties of the
228 mutant strains such as the egress process and the intracellular replication kinetics. The results
229 showed that the majority of tachyzoites of the four *CBDP* mutant strains and the wild-type
230 strain egressed from host cells within 2 min, without any significant differences between all the
231 examined strains (Fig. 3A). We also tested the extent to which the deletion of *CBDP1-4* affects
232 the intracellular growth dynamics of tachyzoites inside the PVs. We found that largest
233 proportion of the vacuoles contained 16 tachyzoites. However, the numbers of tachyzoites
234 inside the PVs were not significantly different between any of the four deletion strains and the
235 wild-type RH strain ($p > 0.05$, Fig. 3B).

236

237 ***CBDP1-4* do not mediate the virulence of *T. gondii* in mice**

238 To gain insight into the role of *CBDP1-4* in the parasite virulence, we inoculated five groups
239 of Kunming mice (6 mice/ group) with 100 tachyzoites of each deletion mutant strain or the
240 wild-type RH strain by i.p. injection. The results showed that all 5 groups of mice reached their
241 humane endpoint between 9 and 12 dpi. The survival time of mice inoculated with each of the
242 four deletion strains was slightly prolonged compared with mice infected by the wild-type
243 strain, however the difference was not significant ($p > 0.05$, Fig. 4).

244

245 **Sequence characteristics and expression patterns of *CBDPs* in *T. gondii***

246 Table 4 summarizes the bioinformatic characteristics of the four *CBDP* genes. We found that
247 none of the four *CBDP* genes had signal peptides. The *CBDP1*, *CBDP3* and *CBDP4* had
248 transmembrane regions, but *CBDP2* did not. Most of the *CBDP* genes were encoded by multiple

249 exons, with *CBDP3* having the largest number. To corroborate the results from the *in vitro* and
250 *in vivo* studies, we analyzed the expression levels of the four genes in different genotypes of *T.*
251 *gondii* strains, parasite cell cycles, and different life-cycle stages. The *CBDP1*
252 (*TGGT1_315520*) did not have any representative transcriptome in the ToxoDB and therefore
253 *CBDP1* was not included in the bioinformatic analysis. The expression profiles of the three
254 *CBDP2-4* genes did not follow a specific cell cycle pattern, with a higher expression of *CBDP3*
255 and a lower expression for *CBDP2* and *CBDP4* (Fig. S2A). Next, we analysed the transcript
256 levels of the 3 *CBDP* genes in different genotypes of *T. gondii* (Type I, Type II and Type III)
257 (Fig. S2B) and found that *CBDP3* of RH strain (genotype I) had a slightly higher expression,
258 compared with the expression levels of *CBDP2* and *CBDP4* of the same strain. However, for
259 Type II and Type III, the expression levels of the three genes were similar. Our analysis revealed
260 that all three *CBDP* genes were differentially expressed at different life cycle stages, with
261 *CBDP4* being significantly higher than *CBDP2* and *CBDP3* in oocysts sporulated for 4 days;
262 the expression of the three *CBDP* genes was lower after 2 days *in vitro* (Fig. S2C).

263

264 **Discussion**

265 The present study was undertaken to identify the role of *CBDP* genes in the pathogenicity and
266 infection process of *T. gondii*. The study did not detect any significant differences in the
267 intracellular replication between the four *CBDP* mutant strains and the wild-type RH strain.
268 Likewise, no significant differences were detected in the parasite egress between the mutant
269 and wild-type strains. Additionally, no significant differences were observed between the wild-
270 type RH strain and any of the four *CBDP* mutant strains in regard to the number or size of
271 plaques, which is a direct reflection of the extent of infection-related cell monolayer damage,
272 and thus, is used as a proxy of *T. gondii* virulence (Liang et al. 2021). These results suggest that
273 the four *CBDP* genes are not essential for *T. gondii* growth, replication, or pathogenicity.

274 We also examined the possibility that these four *CBDP* genes are involved in the parasite
275 virulence. Our *in vivo* data showed that all 5 groups of Kunming mice, infected by RHΔ*CBDP1*,
276 RHΔ*CBDP2*, RHΔ*CBDP3* and RHΔ*CBDP4* or wild-type RH strain, have reached their humane
277 endpoint between 9-12 days. There was no significant difference in the survival rate between
278 mice infected by *CBDP*-mutant-type and those infected by wild-type RH strain. Whether the
279 deletion of *CBDPs* can influence the cyst formation in the mouse brain remains to be
280 investigated.

281 *T. gondii* has a complex life cycle and its development involves alternations between
282 biologically distinct stages, which involves significant transcriptional changes (Chen et al.
283 2018; Radke et al. 2010; Sharma et al. 2020). Likewise, the pathogenic effect of this obligate
284 intracellular parasite requires direct engagement with the host cell in numerous lytic cycles
285 involving cell invasion, intracellular replication and egress, culminating in the destruction of
286 the host cell. The transition between these distinct steps of *T. gondii* lytic cycle is accompanied
287 by marked changes in gene expression (Gaji et al. 2011; Lescault et al. 2010). Furthermore,
288 significant differences were detected in the proteome (Zhou et al. 2017), phosphoproteome
289 (Wang et al. 2019) and post-translational modification (Nie et al. 2022) between *T. gondii*
290 strains of different genetic and virulence backgrounds.

291 In the present study, we characterized the transcriptomic expression levels of *CBDP2-4*
292 genes. Our bioinformatic analysis revealed low expression of *CBDP2-4* in *T. gondii* strains of
293 Types I, II and III, with *CBDP3* of RH strain (genotype I) having a slightly higher expression,
294 compared with the expression levels of *CBDP2* and *CBDP4* of the same strain. Additionally,
295 there were low expression levels and non-significant differences between different phases of
296 the parasite lytic cycle and the different life cycle forms obtained *in vitro* or *in vivo*. These
297 results suggest that the expression profiles of *CBDP* genes were conserved between the
298 different lytic cycle phases, genotypes, and life cycle forms of *T. gondii*. Given the remarkable

299 transcriptomic changes that underpin the parasite alternation between different stages and
300 phases during its developmental cycle (Chen et al. 2018; Fritz et al. 2012; Radke et al. 2005;
301 Sharma et al. 2020) and infection cycle (Gaji et al. 2011; Lescault et al. 2010), the lack of
302 definite differences in the expression patterns of *CBDP2-4* genes across lytic cycle phases,
303 genotypes, life cycle forms is consistent with the non-essential role of *CBDP2-4* genes in the
304 replication and virulence of *T. gondii* RH strain.

305

306 **Conclusion**

307 Here, we examined the biological roles of *CBDP1*, *CBDP2*, *CBDP3* and *CBDP4* in the
308 pathogenicity of *T. gondii* RH strain *in vitro* and *in vivo*. CRISPR-Cas9-mediated disruption
309 of the four *CBDP* genes showed that none of these genes is essential for the parasite virulence
310 or lytic cycle including intracellular replication, plaque formation, and egress. These results
311 were consistent with the high CRISPR fitness and limited transcriptional changes of these genes
312 between the parasite cell cycle phases, genotypes and life cycle forms. Further investigations
313 are required to elucidate the specific roles of other *CBDP* genes in the establishment and
314 maintenance of *T. gondii* infection.

315

316 **Acknowledgments** We thank Professor Bang Shen, Huazhong Agricultural University for
317 providing the pSAG1-Cas9-SgUPRT and pUPRT-DHFR-D vectors.

318

319 **Declarations**

320 **Funding**

321 Project support was provided by the National Natural Science Foundation of China (Grant No.
322 32002306), Fundamental Research Funds of the Chinese Academy of Agricultural Sciences

323 (Grant No. 1610032021017), the Fund for Shanxi “1331 Project” (Grant No. 20211331-13),
324 The Agricultural Science and Technology Innovation Program (ASTIP) of China (Grant No.
325 CAAS-ASTIP-2016-LVRI-03), the Yunnan Expert Workstation (Grant No. 202005AF150041)
326 and the Veterinary Public Health Innovation Team of Yunnan Province (Grant No.
327 202105AE160014).

328

329 **Conflicts of interest**

330 The authors declare that they have no competing interests.

331

332 **Availability of data and material**

333 The datasets supporting the findings of this article are included within the paper and its
334 supplementary materials.

335

336 **Authors' contributions**

337 Xing-Quan Zhu, Meng Wang, Jin-Lei Wang and Hany M. Elsheikha conceived and designed
338 the study. Xin-Cheng Wang performed the experiments, analysed the data and wrote the
339 manuscript. Ting-Ting Li, Xiao-Nan Zheng and Dan-Yu Zhao participated in the
340 implementation of the study. Meng Wang and Jin-Lei Wang contributed
341 reagents/materials/analysis tools. Hany M. Elsheikha, Xing-Quan Zhu and Meng Wang
342 critically revised the manuscript. All authors read and approved the final version of the
343 manuscript.

344

345 **Ethics approval**

346 All animal studies were carried out in accordance with protocols reviewed and approved by the
347 Research Ethics Committee of Lanzhou Veterinary Research Institute, Chinese Academy of
348 Agricultural Sciences. All animals were handled strictly according to the Animal Ethics

349 Procedures and Guidelines of the People's Republic of China. All efforts were made to
350 minimize the number of mice used in the study.

351

352 **Consent to participate**

353 Not applicable.

354

355 **Consent for publication**

356 Not applicable.

357

358 **Supplementary Information**

359 The online version contains supplementary material available at: xxxx

360

361 **References**

362

363 Appella E, Weber IT, Blasi F (1988) Structure and function of epidermal growth factor-like
364 regions in proteins. FEBS Lett 231(1):1-4

365 Behnke MS, Wootton JC, Lehmann MM, Radke JB, Lucas O, Nawas J, Sibley LD, White MW
366 (2010) Coordinated progression through two subtranscriptomes underlies the tachyzoite
367 cycle of *Toxoplasma gondii*. PLoS One 5:e12354

368 Billker O, Lourido S, Sibley LD (2009) Calcium-dependent signaling and kinases in
369 apicomplexan parasites. Cell Host Microbe 5(6):612-622

370 Blomquist MC, Hunt LT, Barker WC (1984) Vaccinia virus 19-kilodalton protein: relationship
371 to several mammalian proteins, including two growth factors. Proc Natl Acad Sci U S A
372 81(23):7363–7367

373 Borges-Pereira L, Budu A, McKnight CA, Moore CA, Vella SA, Hortua Triana MA, et al.
374 (2015) Calcium signaling throughout the *Toxoplasma gondii* lytic cycle: A Study using
375 genetically encoded calcium indicators. J Biol Chem 290(45):26914-26926

376 Chen LF, Han XL, Li FX, Yao YY, Fang JP, Liu XJ, Li XC, Wu K, Liu M, Chen XG (2018)
377 Comparative studies of *Toxoplasma gondii* transcriptomes: insights into stage conversion
378 based on gene expression profiling and alternative splicing. Parasit. Vectors 11, 402

379 Davis CG (1990) The many faces of epidermal growth factor repeats. New Biol 2(5):410–419

380 Doolittle RF, Feng DF, Johnson MS (1984) Computer-based characterization of epidermal
381 growth factor precursor. Nature 307(5951):558–560

382 Elsheikha HM (2008) Congenital toxoplasmosis: priorities for further health promotion action.
383 Public Health 122(4):335-353

384 Elsheikha HM, Marra CM, Zhu XQ (2021) Epidemiology, pathophysiology, diagnosis, and
385 management of cerebral toxoplasmosis. Clin Microbiol Rev 34(1):00115-19

386 Fritz HM, Buchholz KR, Chen X, Durbin-Johnson B, Rocke DM, Conrad PA, Boothroyd JC
387 (2012) Transcriptomic analysis of *Toxoplasma* development reveals many novel functions
388 and structures specific to sporozoites and oocysts. PloS one 7(2):e29998

389 Gaji RY, Behnke MS, Lehmann MM, White MW, Carruthers VB (2011) Cell cycle-dependent,
390 intercellular transmission of *Toxoplasma gondii* is accompanied by marked changes in
391 parasite gene expression. Mol Microbiol 79:192–204

392 Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, Heiges M, Iodice J, Kissinger J,
393 Mackey A, Pinney D, Roos D, Stoeckert C, Wang HM, Brunk B (2007) ToxoDB: an
394 integrated *Toxoplasma gondii* database resource. Nucleic Acids Res 36(Database
395 issue):D553-556

396 Garcia-Réguet N, Lebrun M, Fourmaux MN, Mercereau-Puijalon O, Mann T, Beckers CJ,
397 Samyn B, Van Beeumen J, Bout D, Dubremetz JF (2000) The microneme protein MIC3
398 of *Toxoplasma gondii* is a secretory adhesin that binds to both the surface of the host cells
399 and the surface of the parasite. Cell Microbiol 2(4):353-364

400 Garrison E, Treeck M, Ehret E, Butz H, Garbuz T, Oswald B, Settles M, Boothroyd J,
401 Arrizabalaga G (2012) A forward genetic screen reveals that calcium-dependent protein
402 kinase 3 regulates egress in *Toxoplasma*. PLoS Pathog 8(11):e1003049

403 Kannan G, Thaprawat P, Schultz TL, Carruthers VB (2021) Acquisition of host cytosolic
404 protein by *Toxoplasma gondii* bradyzoites. mSphere 6(1):e00934-20

405 Kursula P (2014) The many structural faces of calmodulin: a multitasking molecular jackknife.
406 Amino acids 46(10):2295–2304

407 Lescault PJ, Thompson AB, Patil V, Lirussi D, Burton A, Margarit J, Bond J, Matrajt M (2010)
408 Genomic data reveal *Toxoplasma gondii* differentiation mutants are also impaired with
409 respect to switching into a novel extracellular tachyzoite state. PLoS ONE 5:e14463

410 Liang QL, Nie LB, Li T. T., Elsheikha HM, Sun LX, Zhang ZW, Zhao D.Y, Zhu X.Q, Wang
411 JL (2021) Functional characterization of 17 protein serine/threonine phosphatases in
412 *Toxoplasma gondii* using CRISPR-Cas9 system. Front Cell Dev Biol 9(10):738794

413 Long S, Wang Q, Sibley LD (2016) Analysis of noncanonical calcium-dependent protein
414 kinases in *Toxoplasma gondii* by targeted gene deletion using CRISPR/Cas9. Infect
415 Immun 84(5):1262-1273

416 Long S, Brown KM, Drewry LL, Anthony B, Phan IQH, Sibley LD (2017) Calmodulin-like
417 proteins localized to the conoid regulate motility and cell invasion by *Toxoplasma gondii*.
418 PLoS Pathog 13(5):e1006379

419 Lourido S, Jeschke GR, Turk BE, Sibley LD (2013) Exploiting the unique ATP-binding pocket
420 of *Toxoplasma* calcium-dependent protein kinase 1 to identify its substrates. ACS Chem
421 Biol 8(6):1155-1162

422 Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley L. D (2010) Calcium-dependent
423 protein kinase 1 is an essential regulator of exocytosis in *Toxoplasma*. Nature
424 465(7296):359-362

425 Lovett JL, Sibley LD (2003) Intracellular calcium stores in *Toxoplasma gondii* govern invasion
426 of host cells. J Cell Sci 116(Pt 14):3009-3016

427 McCoy JM, Whitehead L, van Dooren GG, Tonkin CJ (2012) TgCDPK3 regulates calcium-
428 dependent egress of *Toxoplasma gondii* from host cells. PLoS Pathog 8(12):e1003066

429 Moreno SNJ, Docampo R (2003) Calcium regulation in protozoan parasites. Curr Opin
430 Microbiol 6(4):359-364

431 Moreno SNJ, Ayong L, Pace DA (2011) Calcium storage and function in apicomplexan
432 parasites. Essays Biochem 51:97-110

433 Morlon-Guyot J, Berry L, Chen CT, Gubbels MJ, Lebrun M, Daher W (2014) The *Toxoplasma*
434 *gondii* calcium-dependent protein kinase 7 is involved in early steps of parasite division
435 and is crucial for parasite survival. *Cell Microbiol* 16(1):95-114

436 Nagamune K, Sibley LD (2006) Comparative genomic and phylogenetic analyses of calcium
437 ATPases and calcium-regulated proteins in the apicomplexa. *Mol Biol Evol* 23(8):1613–
438 1627

439 Nagamune K, Moreno SN, Chini EN, Sibley LD (2008) Calcium regulation and signaling in
440 apicomplexan parasites. *Subcell Biochem* 47:70-81

441 Nie LB, Liang QL, Wang M, Du R, Zhang MY, Elsheikha HM, Zhu XQ (2022) Global profiling
442 of protein lysine malonylation in *Toxoplasma gondii* strains of different virulence and
443 genetic backgrounds. *PLoS Negl Trop Dis* 16(5):e0010431

444 Pingret L, Millot JM, Sharonov S, Bonhomme A, Manfait M, Pinon JM (1996) Relationship
445 between intracellular free calcium concentrations and the intracellular development of
446 *Toxoplasma gondii*. *J Histochem Cytochem* 44(10):1123-1129

447 Radke JB, Lucas O, Nawas J, Sibley LD, White MW (2010) Coordinated progression through
448 two subtranscriptomes underlies the tachyzoite cycle of *Toxoplasma gondii*. *PloS one*
449 5(8):e12354

450 Radke JR, Behnke MS, Mackey AJ, Radke JB, Roos DS, White MW (2005) The transcriptome
451 of *Toxoplasma gondii*. *BMC Biol* 3:26

452 Rico-Torres CP, Vargas-Villavicencio JA, Correa D (2016) Is *Toxoplasma gondii* type related
453 to clinical outcome in human congenital infection? systematic and critical review. *Eur J*
454 *Clin Microbiol Infect Dis* 35(7):1079-1088

455 Robert-Gangneux F, Dardé ML (2012) Epidemiology of and diagnostic strategies for
456 toxoplasmosis. Clin Microbiol Rev 25(2):264-296

457 Selander-Sunnerhagen M, Ullner M, Persson E, Teleman O, Stenflo J, Drakenberg T (1992)
458 How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR
459 structure of the calcium form of the NH₂-terminal EGF-like domain in coagulation factor
460 X. J Biol Chem 267(27):19642-19649

461 Sharma J, Rodriguez P, Roy P, Guiton PS (2020) Transcriptional ups and downs: patterns of
462 gene expression in the life cycle of *Toxoplasma gondii*. Microbes Infect. 22(10):525-533

463 Shen B, Sibley LD (2014) *Toxoplasma* aldolase is required for metabolism but dispensable for
464 host-cell invasion. Proc Natl Acad Sci U S A 111(9):3567-3572

465 Smith NS, Goulart C, Hayward JA, Kupz A, Miller CM, van Dooren GG (2021) Control of
466 human toxoplasmosis. Int J Parasitol 51(2-3):95-121

467 Uboldi AD, McCoy JM, Blume M, Gerlic M, Ferguson DJP, Dagley LF, Beahan CT, Stapleton
468 DI, Gooley PR, Bacic A, Masters SL, Webb AI, McConville MJ, Tonkin CJ (2015)
469 Regulation of starch stores by a Ca²⁺-dependent protein kinase is essential for viable cyst
470 development in *Toxoplasma gondii*. Cell Host Microbe 18(6):670-681

471 Wang JL, Bai MJ, Elsheikha HM, Liang QL, Li TT, Cao XZ, Zhu XQ (2020a) Novel roles of
472 dense granule protein 12 (GRA12) in *Toxoplasma gondii* infection. FASEB J 34(2):3165-
473 3178

474 Wang JL, Li TT, Elsheikha HM, Chen K, Cong W, Yang WB, Bai MJ, Huang SY, Zhu XQ
475 (2018) Live attenuated Pru:Δcdpk2 strain of *Toxoplasma gondii* protects against acute,
476 chronic, and congenital toxoplasmosis. J Infect Dis 218(5):768-777

477 Wang JL, Liang QL, Li TT, He JJ, Bai MJ, Cao XZ, Elsheikha HM, Zhu XQ (2020b)
478 *Toxoplasma gondii* tk11 deletion mutant is a promising vaccine against acute, chronic, and
479 congenital toxoplasmosis in mice. J Immunol 204(6):1562-1570

480 Wang JL, Zhang NZ, Li TT, He JJ, Elsheikha HM, Zhu XQ (2019) Advances in the
481 development of anti-*Toxoplasma gondii* vaccines: challenges, opportunities, and
482 perspectives. Trends Parasitol 35(3):239-253

483 Wang S, Hassan IA, Liu X, Xu L, Yan R, Song X, Li X (2015) Immunological changes induced
484 by *Toxoplasma gondii* glutathione-S-transferase (TgGST) delivered as a DNA vaccine.
485 Res Vet Sci 99:157-164

486 Wang ZD, Wang C, Liu HH, Ma HY, Li ZY, Wei F, Zhu XQ, Liu Q (2017) Prevalence and
487 burden of *Toxoplasma gondii* infection in HIV-infected people: a systematic review and
488 meta-analysis. Lancet HIV 4(4):e177-e188

489 Wang ZX, Zhou CX, Calderón-Mantilla G, Petsalaki E, He JJ, Song HY, Elsheikha HM, Zhu
490 XQ (2019) iTRAQ-based global phosphoproteomics reveals novel molecular differences
491 between *Toxoplasma gondii* strains of different genotypes. Front Cell Infect Microbiol.
492 29:307

493 Wu, M., An, R., Zhou, N., Chen, Y., Cai, H., Yan, Q., Wang, R., Luo, Q., Yu, L., Chen, L., &
494 Du, J (2022) *Toxoplasma gondii* CDPK3 controls the intracellular proliferation of
495 parasites in macrophages. Front Immunol 13:905142

496 Zhang D, Jiang N, Chen Q (2019) ROP9, MIC3, and SAG2 are heparin-binding proteins in
497 *Toxoplasma gondii* and involved in host cell attachment and invasion. Acta Trop 192:22-
498 29

499 Zhang H, Liu J, Ying Z, Li S, Wu Y, Liu Q (2020) *Toxoplasma gondii* UBL-UBA shuttle
500 proteins contribute to the degradation of ubiquitinated proteins and are important for
501 synchronous cell division and virulence. *FASEB J* 34(10):13711-13725

502 Zhou DH, Wang ZX, Zhou CX, He S, Elsheikha HM, Zhu XQ (2017) Comparative proteomic
503 analysis of virulent and avirulent strains of *Toxoplasma gondii* reveals strain-specific
504 patterns. *Oncotarget* 8(46):80481-80491

505

506

507 **Table 1** Construction of the *CBDP* knockout *T. gondii* RH strains.

Primer name	Sequence (5' → 3')
Sg-315520	<u>GCGGCGATTATCGAGAGCTAGTTTTAGAGCTAGAAATAGC</u>
Sg-318540	<u>GATCATCTCCTCTAACAAGTGT</u> TTTTAGAGCTAGAAATAGC
Sg-269930	<u>GAAGACAACGAACCAGGCCAGTTTTAGAGCTAGAAATAGC</u>
Sg-315550	<u>GGTTATACGGAGACCAGCGCGTTTTAGAGCTAGAAATAGC</u>

508 Note: The underlined sequence is the sgRNA.

509

510

511

512

513 **Table 2** Primers for amplification of homologous fragments.

Primer name	Sequence (5' → 3')
U5-315520-F	GGTTTTCCCAGTCACGACGTTTCTGGGAGGAAGGACACGAGCAA
U5-315520-R	GGATTTACAGCCTGGCGAAGCTTTTTCAACCCCTGAGCGAAAAGC
U3-315520-F	CTATGCACTTGCAGGATGAATTCTATGCTTCGGTCTTTTATGTTCTGG
U3-315520-R	GAGCGGATAACAATTTACAACGCCAACTGGTCGGGTGATT
U5-318540-F	GGTTTTCCCAGTCACGACGTTAGCCTCTTGCGGAGTCTTGTGG
U5-318540-R	GGATTTACAGCCTGGCGAAGCTTGTATGCTGGCACCGACGGAGAT
U3-318540-F	CTATGCACTTGCAGGATGAATTCGGAAGTGGCTGCTGGCGTTTT
U3-318540-R	GAGCGGATAACAATTTCACACATCGGTTTCGTAATTCATTGTTATTGTCT
U5-269930-F	GGTTTTCCCAGTCACGACGTTTGTGTTGGAGGGAGGCTAGAAGTGC
U5-269930-R	GGATTTACAGCCTGGCGAAGCTTACGATAGAAGACGCCGAAATGGTTA
U3-269930-F	CTATGCACTTGCAGGATGAATTCCTCAGCAACATCGTTCCACCCC
U3-269930-R	GAGCGGATAACAATTTACAATATTTCTTGTCCAGAAACCGGATTACAT
U5-315550-F	GGTTTTCCCAGTCACGACGTTGCTGCTGCTTGGCTTCCCTCA
U5-315550-R	GGATTTACAGCCTGGCGAAGCTTTGTCCTTTCGGTTGAAAATGTCGC
U3-315550-F	CTATGCACTTGCAGGATGAATTCGAAGGTTGTGCGGGGCAGGTC
U3-315550-R	GAGCGGATAACAATTTACATGGCTTCGATGGTTGTCTTCCAG

514 Note: The underlined sequences are designed to amplify homologous fragments.

515
516
517
518
519
520
521
522
523
524
525
526
527
528

529 **Table 3** Primers used for the confirmation of the targeted gene deletion.

Primer name	Sequence (5' → 3')
315520-PCR1-F	GGGAAGGAAATGCACGGTGGATTA
315520-PCR2-F	CCACTTAGATGGGACGGGATTGC
315520-PCR2-R	TGAGTGAGACAGTGCTTCCACCAGA
315520-PCR3-R	CTCCGACTTTCGAGATTTCGCTT
318540-PCR1-F	TTCTGCCCCTTCACAACCACAGTT
318540-PCR2-F	CGGAGGATTTGAATGCGGTTGC
318540-PCR2-R	CCCGATGTTAGTTTTGGTGATGTTTG
318540-PCR3-R	GCCGAGTGCGATAAGAGTGATTGT
269930-PCR1-F	CGCATGAGAACGTTGGTTCACCTG
269930-PCR2-F	GTCTTAGGATTTGATGCTTGTCTGATGG
269930-PCR2-R	GAAGTGAAAAGTAACAGGAGCTGGGTC
269930-PCR3-R	GTTTGCGCACAGAAACTGGCATGT
315550-PCR1-F	CCCAGCAGTTGATCGATCTCGATA
315550-PCR2-F	CAACGGATTTTCGTCTAATGAGGTCTT
315550-PCR2-R	CCATCGGACTCCTGGCTGACC
315550-PCR3-R	AAGGTTCTGTTCTGCCTCTTCCGA
PCR1-R	GCCAAAGTAGAAAGGAATTAGCAT
PCR3-F	TGACGCAGATGTGCGTGTATCCAC

530

531

532

533

Table 4 Bioinformatics features of the CBDPs of *Toxoplasma gondii*.

Name	Gene ID	Product description	Exons	Phenotype value	TMHMM ^a	Molecular weight (kD ^a)	Predicted signal peptide
<i>CBDP1</i>	TGME49_315520	Calcium binding egf domain-containing protein	8	1.04	Yes	36.589	No
<i>CBDP2</i>	TGME49_318540	Calcium binding egf domain-containing protein	2	0.77	No	72.334	No
<i>CBDP3</i>	TGME49_269930	Calcium binding egf domain-containing protein	13	-0.14	Yes	337.852	No
<i>CBDP4</i>	TGME49_315550	Calcium binding egf domain-containing protein	7	0.85	Yes	33.195	No

534

Note: ^a Prediction of transmembrane helices was carried out using the TMHMM, program version 2.0.

535

536

537

538


539

540

541

542 **Figures:**

543



544

545 **Fig. 1** Construction of the *CBDP* knockout strains using CRISPR-cas9 technology. **A**

546 Schematic diagram showing the disruption of the targeted *CBDP* genes. **B** The knockout strains

547 (RH Δ CBDP1, RH Δ CBDP2, RH Δ CBDP3 and RH Δ CBDP4) were verified by PCR analysis.

548 PCR1 and PCR3 amplified ~ 1500 bp band in knockout strains, while wild-type RH strain had

549 no band, indicating that DHFR fragments were successfully inserted into knockout strains from


550 5' to 3' ends by homologous recombination. PCR2 showed that ~ 600 bp band was amplified in

551 the wild-type RH strain, while knockout strains had no bands, showing that the targeted genes

552 were successfully deleted.

553

554



555

556

557

558 **Fig. 2** The plaque formation of *CBDP* knockout strains compared with wild-type RH strain *in*
559 *vitro*. HFF monolayers were infected by 500 tachyzoites for 7 days and stained with crystal
560 violet to determine the number of plaques. **A** Representative photographs of the plaques
561 detected in HFFs infected by the 4 RHΔ*CBDP1-4* strains and those produced by the wild-type
562 RH strain. **B** The relative size of the plaques generated by *CBDP1-4* mutant strains versus the
563 wild-type RH strain showing no significant differences between RH strain and any *CBDP*
564 mutant strains. n.s, not significant, one-way ANOVA.

565

566

567


568

569

570

571

572
573
574
575
576



577

578 **Fig. 3** Egress process and intravacuolar replication of the *CBDP* knockout strains and wild-type
579 RH strains *in vitro*. After inoculation of 2×10^4 tachyzoites of the *CBDP* mutant and wild type
580 RH strains into HFF monolayers grown in 12 plates for 28-32 h, the culture medium was
581 discarded. The tachyzoite exist of the host cells was recorded after adding 3 μ M of calcium
582 ionophore A23187. **A** Representative images showing that one of the *CBDP1-4* mutant strains
583 (RHΔ*CBDP1*) and the wild-type RH strain egress during 2 min after adding 3 μ M calcium
584 ionophore A23187. **B** The percentages of the parasitophorous vacuoles containing tachyzoites
585 (1, 2, 4, 8, and 16 tachyzoites per vacuole). The wild-type RH strain and the *CBDP1-4* mutant
586 strains had roughly similar intracellular replication dynamics. n.s., not significant, two-way
587 ANOVA.

588

589


590

591

592

593

594



595

596 **Fig. 4** Survival curve of the Kunming mice infected by the *CBDP* mutant strains and wild-type

597 RH strain of *T. gondii*. The mice (6/group) were intraperitoneally injected with 100 tachyzoites

598 of each strain. Following infection, the mice reached their humane endpoint within 9 to 12 days

599 after infection. Statistical analysis was performed with GraphPad Prism. Log-rank (Mantel-Cox)

600 tests and revealed no statistically significant differences ($p > 0.05$)

601

602

603

604

605


606

607

608

609

610 **Supplementary information**



611


612 **Fig. S1** The schematic diagram of the predicted functional domains in each CBDP protein. EGF,
 613 epidermal growth factor-like domain; EGF-CA, calcium-binding EGF-like domain; EGF-like,
 614 EGF domain, unclassified subfamily. The putative functional domains of the CBDP proteins
 615 were predicated by the SMART algorithm (<http://smart.embl-heidelberg.de>). The blue
 616 rectangles represent the transmembrane helix region, as detected by the TMHMM v2.0 program.

617

618

619

620



621

622 **Fig. S2** The expression profiles of *Toxoplasma gondii* CBDPs. **A** The expression profile of 3

623 CBDP genes of *T. gondii* RH strain presented by the cell cycle phases. **B** The expression profiles

624 of 3 CBDP genes in Type I (RH and GT1), Type II (Pru and ME49), and Type III (CTG and

625 VEG) strains. **C** The expression profiles of 3 CBDP genes related to the parasite life cycle

626 stages (oocyst, tachyzoite and bradyzoite). Expression profile of 3 CBDP genes of the oocysts

627 recovered from cat feces at 0 day (unsporulated), 4 days (4 days sporulated), and 10 days (10

628 days sporulated), tachyzoites grown for 2 days in HFF cells (2 days *in vitro*), bradyzoites grown

629 in HFF cells for 4 days and 8 days (4 day *in vitro* and 8 days *in vitro*), and 21 days tissue cyst-

630 containing bradyzoites harvested from infected mouse brains (21 days *in vivo*). Each line

631 represents the expression value of the corresponding gene.

632